As of Wednesday close, Atai Life Sciences N.V.’s (NASDAQ:ATAI) stock was up $0.06, moving up 3.73 percent to $1.67. The average number of shares traded per day over the past five days has been 602,920 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0900 fall in that time frame. In the last twenty days, the average volume was 701,010, while in the previous 50 days, it was 1,085,434.
Since last month, ATAI stock retreated -26.75%. Shares of the company fell to $1.5700 on 08/16/23, the lowest level in the past month. A 52-week high of $4.96 was reached on 01/04/23 after having rallying from a 52-week low of $1.14. Since the beginning of this year, ATAI’s stock price has dropped by -37.22% or -$0.9900, and marked a new high 2 times. However, the stock has declined by -66.33% since its 52-week high.
ATAI stock investors should be aware that Atai Life Sciences N.V. (ATAI) stock had its last reported insider trading activity 141 days ago on Mar 29. Apeiron Investment Group Ltd., the 10% Owner of the company, purchased of 1,214,297 shares for $1.32 on Mar 29. It resulted in a $1,600,443 investment by the insider. Brand Florian added 70,000 shares at an average price of $1.48 on Mar 29. The insider now owns 70,000 shares following the transaction.
Valuation Metrics
The stock’s beta is 0.84. Besides these, the trailing price-to-sales (P/S) ratio of 940.71, the price-to-book (PB) ratio of 1.23.
The latest dividend of $6.00 per share was paid out, which is 1363.41% more than last year’s $0.41.
Financial Health
In the three months ended June 29, Atai Life Sciences N.V.’s quick ratio stood at 13.50, while its current ratio was 13.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.07, and the total debt-to-equity ratio was 0.07. Based on annual data, ATAI earned $145.02 million in gross profit and brought in $0.23 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -54.20%. Return on equity (ROE) for the past 12 months was -58.10%.
In Atai Life Sciences N.V.’s quarter-end financial report for June 29, it reported total debt of $14.87 million against cash and short-term investments of $86.4 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ATAI’s revenue fell 0.0% during the quarter, while net income inched up to $0.17 million. While analysts expected Atai Life Sciences N.V. to report -$0.21 quarterly earnings, the actual figure was -$0.21 per share. During the quarter, the company generated -$31.78 million in EBITDA. The liabilities of Atai Life Sciences N.V. were 37.96 million at the end of its most recent quarter ended June 29, and its total debt was $19.0 million. The value of shareholders’ equity is $166.01 million.
Technical Picture
This quick technical analysis looks at Atai Life Sciences N.V.’s (ATAI) price momentum. With a historical volatility rate of 44.31%, the RSI 9-day stood at 31.88% on 16 August.
With respect to its five-day moving average, the current Atai Life Sciences N.V. price is down by -5.11% percent or -$0.0900. At present, ATAI shares trade -22.69% below its 20-day simple moving average and +40.34% percent above its 100-day simple moving average. However, the stock is currently trading approximately -8.24% below its SMA50 and -44.15% below its SMA200.
Stochastic coefficient K was 9.45% and Stochastic coefficient D was 8.25%, while ATR was 0.1087. Given the Stochastic reading of 18.52% for the 14-day period, the RSI (14) reading has been calculated as 37.00%. As of today, the MACD Oscillator reading stands at -0.0733, while the 14-day reading stands at -0.1819.
Analyst Ratings
Loop Capital launched its rating on Atai Life Sciences N.V. (NASDAQ: ATAI) to a Buy in a note to investors on November 01, 2022. Atai Life Sciences N.V. (ATAI) has been rated Buy by analysts. According to 0 brokerage firms, ATAI is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Atai Life Sciences N.V. stock as buy, with 10 recommending it as overweight.
With a median target price of $11.00, the current consensus forecast for the stock is $5.10 – $21.00. Based on these forecasts, analysts predict Atai Life Sciences N.V. (ATAI) will achieve an average price target of $11.90.
